ArticleJournal of cachexia, sarcopenia and muscle2025
Exogenous Nucleotides Supplementation Attenuates Age-Related Sarcopenia.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dietary Nucleotides as Potential Modulators of Inflammatory and Metabolic Pathways with Implications for Insulin Resistance.International journal of molecular sciences · 2026Review
- The antiparasitic drug Nitazoxanide enhances the susceptibility of Candida albicans to fluconazole.BMC microbiology · 2026Article
- Integrated bioinformatics and mendelian randomization reveal a six-gene diagnostic signature and key role of CYP26B1 in sarcopenia.Frontiers in molecular biosciences · 2026Article
- Exogenous Nucleotides Supplementation Attenuates Age-Related Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, an age-related clinical syndrome characterized by reduced skeletal muscle mass and strength, often leads to a loss of physical function. Nucleotides (NTs) supplementation is a potential strategy for preventing age-related sarcopenia as evidence suggests that NTs declined in muscles with aging, and 5'-CMP, 5'-UMP can mitigate muscle atrophy in C2C12 myotubes. This study aimed to investigate the effects of NTs supplementation on sarcopenia and its possible mechanism.
methodsSenescence-accelerated mouse prone-8 (SAMP8) mice and C2C12 cells were used to assess the effect of NTs on sarcopenia. We fed an NTs-enriched mixture to SAMP8 mice starting from the age of 3 months for 9 months or 15 months. NTs' effects on H
resultsThe results demonstrated that NTs significantly increased lean mass/body weight (p < 0.01, η
conclusionsOur findings reveal the protective role of NTs in improving muscle protein balance during ageing, suggesting they may serve as a conditionally essential nutrient for older individuals. Further research is needed to explore the efficacy and safety of NTs supplementation for sarcopenia in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.